jnj-63733657
mAbexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 22, 2017 (NCT03375697)
Timeline
Indications
Mechanism of action
- Microtubule-associated protein tauINHIBITOR
MAPT inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- jnj-63733657
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05407818 | Phase 1 | Jun 27, 2022 | — |
| NCT04619420 | Phase 2 | Jan 6, 2021 | Janssen Pharmaceutica NV |
| NCT03689153 | Phase 1 | Oct 1, 2018 | Janssen Pharmaceutica NV |
| NCT03375697 | Phase 1 | Dec 22, 2017 | Johnson and Johnson |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Janssen Pharmaceutica NV | For profit | 2 | 2 | 2 | 2018 |
| Johnson and Johnson | For profit | 1 | 1 | 1 | 2017 |
2 organizations
Page 1 / 1